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Asthma treatment: Clinical trials
0109
COMPARISON OF ORAL VERSUS INHALED NONSTEROIDAL 
THERAPIES IN THE TREATMENT OF PATIENTS WITH MILD TO 
MODERATE ASTHMA
R.A. Nathan*, M. Glass, L. Snader; Allergy Associates, PC, Colorado 
Springs, CO*, ZENECA Pharmaceuticals, Wilmington, DE.
The efficacy and safety of zafiriukast (ACCOLATE™) were compared with 
cromolyn sodium (INTAL®) and placebo in a multicenter, double-blind, 
double-dummy, parallel-group study. Patients (n-287) 12 to 71 years of age 
with self-assessed, mild-to-moderate asthma and a cumulative daytime asthma 
symptom score £8 over 7 consecutive days (range, 0 to 3 per day) were 
randomized to 13 weeks of treatment with zafiriukast (20 mg, bid), cromolyn 
sodium (2 puffs = 1600 Jig, qid), or placebo. Albuterol was provided as 
rescue medication. Response to treatment was assessed by the percentage of 
patients who met SI of the following response criteria: 50% reduction in 
daytime symptoms, first morning symptoms, or nocturnal awakenings with­
out a 50% increase in p-agonist use, or a 50% decrease in (i-agonist use 
without a 50% increase in daytime symptoms. More patients responded to 
treatment with zafiriukast (64%) and cromolyn sodium (68%) than with 
placebo (46%, p<0.05); no difference was observed between active treat­
ments (p>0.10). The safety profile for active therapies was not clinically 
different than that of placebo. The proposed minimum dose of zafiriukast (20 
mg, bid) was comparable in safety and efficacy to the optimum dose of 
cromolyn sodium (2 puffs, qid) in patients with mild-to-moderate asthma 
appropriate for first-line therapy.
0110
LONG ACTING 02 AGONISTS: A COMPARISON OF ORAL 
BAMBUTEROL AND INHALED SALMETEROL IN ASTHMATIC 
PATIENTS W ITH NOCTURNAL SYMPTOMS
B. Wailaert* and the French Bambuterol Study Group, J. Ostinelli** 
and B. Arnould**. *CHU Calmette, Lille, France. **Laboratoires 
Astra France Nanterre, France.
The effect of bambuterol 20 mg at bedtime and of salmeterol 50 fig bid was 
compared in a multi centre study comprising a 2-week run-in and a 6-week 
double-blind double-dummy treatment period, with a randomized, parallel 
group design. 117 asthmatic patients (65F/52M) aged 20 to 70 years (mean 
45) were randomized. They were to be treated with inhaled steroids 800 to 
2,000 pg daily and/or oral steroids < 20 mg/daily for at least 4 weeks, to 
have a nocturnal wakening due to asthma symptoms with a need for rescue 
medication at least once during the run-in, > 15 % overnight fall of peak 
expiratory flow (PEF) in 3 out of the last 7 days of the run-inv and 40 ^  
FEV1 < 85 % of predicted normal. The patients recorded morning and 
evening PEF, daily symptom score (0-3), rescue medication and subjective 
tremor score (0-3) in a diary. The primary variable was morning PEF, change 
from run-in. Main results were as follows:
Bambuterol Salmeterol p value
FEVI at visit 1(% pred) 64±I2 65±I3 NS
ÀPEF morning* 28±51 29±52 NS
(L/min)
ÀPEF evening* 20±53 23±53 NS
(Umin)
nocturnal awakening (%/week)
- run-in 46±30 48+30 NS
- active treatment 18 ±25 25±31 NS
* change from run-in, mean±SD.
Other efficacy variables (daily symptoms score, rescue medication, overnight 
fall of PEF) showed a similar improvement in both groups. Tremor scores 
were low and similar in both groups during the run-in and treatment periods 
(mean±SD: bambuterol 0,2±0,5 and 0,2±0,3; salmeterol 0,3±0,6 and 
0,2±0,4), Five serious adverse events occurred during the study among 
which 4 deteriorations of asthma (salmeterol n=3, bambuterol n=*l). In 
conclusion, similar efficacy and control of nocturnal and daily symptoms of 
asthma were obtained with oral bambuterol 20 mg at bedtime and inhaled 
salmeterol 50 pg bid in this group of moderate to severe asthmatic patients.
0111
0,5% NEDOCROMIL SODIUM NEBULISER SOLUTION IN MILD- 
TO-MODERATE ASTHMA PATIENTS
S. Galant, J . Gadde, M. Kraemer, M. Noonan, L. Southern, J . Taylor,
R. Webb, S. Weinstein, Orange, CA; Green belt, MD; Spokane, WA;
Portland, OR; Princeton, NJ; Tacoma, WA; Kirkland, WA; Huntington 
Beach, CA; USA.
Using a double-blind, placebo controlled, parallel group study design, we 
have evaluated the efficacy and safety of 0.5% nedocromil sodium (Tilade®) 
nebuliser solution in mild-to-moderate asthma patients. Nebuliser solutions, 
administered four times daily for 12 weeks* were randomly allocated to 188 
symptomatic asthma patients (age range 12-81; mean 33 years). Eight cen­
tres took part, with 94 patients in each treatment group. Both treatments 
were safe and well tolerated. All the diary card and clinic variables showed 
differences in favour of nedocromil sodium compared with placebo, these 
being statistically significant for:
sum m ary score§
nedocromil sodium 
placebo 
sleep difficulty 
nedocromil sodium 
placebo
a.m. peak flow (L/rain)
nedocromil sodium 
placebo
p.m. peak flow (L/min)
nedocromil sodium 
placebo
FEF2s_75 (L/Sec) 
nedocromil sodium 
placebo
baseline weeks 3-121 p-value
3.41 2.49 0 .0 2 8
3.32 2 .95
0.98 0.70 0 .0 2 8
0,98 0 .89
386 411 0 .0 5 0
376 390
406 442 0 .0 0 2
407 4 0 9
1.98 2.20 0 .011
1.99 2 ,03
|  primary time period of assessment 
§ main efficacy variable (daytime asthma + sleep difficulty)
0112
IMPROVEMENTS IN QUALITY OF L IF E  IN  CHRONIC ORAL 
STEROID-DEPENDENT ASTHMA PATIENTS USING FLU TIC A SO N E 
PROPIONATE ARE MAINTAINED ONE YEAR LATER 
L. Okamoto*, D. Kellerraan*, J. Larsen**, S. W eisberg**. *Rescarch 
Triangle Park, North Carolina, **i\linneapolis, M innesota, USA.
The purpose of this study was to assess quality of life (QOL) associated with 
long-term use of fluticasone propionate (FP) in chronic oral steroid- 
dependent patients. Previously, we reported that patients receiving inhaled 
fluticasone propionate (IGOGmcg or 750mcg twice daily) experienced sig­
nificant improvements in key dimensions of QOL (Jolicoeur, L. et al. JACI 
1994: 93: 185.). Following this study, ninety-one (91) patients were en­
tered into an open-label extension receiving FP in doses of 250-1000m cg 
twice daily. Patients completed the Medical Outcomes Study Short Form 3 6  
and Sleep Scale at pre-study, and at 4» 8, and 12 months of extension. QOL 
scale scores range from 0-100 with higher scores reflecting better QOL.
Pre-study Month 4 Month 8 Month 12
Physical 60.8 73 .5 73.8 73 .3
Functioning
Role-Physical 48.1 66.5 63.4 6 2 .2
General Health 53.5 63.4 63.3 62 .9
Vitality 51,9 60 .4 60.0 60.1
Change in Health 5 8 .Î 85.6 85.8 85 .5
Sleep 48.9 62 .2 63 ,2 6 1 .2
Patients experienced an improvement in six QOL dimensions, ranging from 
8 to 27 pointa, after receiving FP for I year. Overall, long-term use of FP in  
patients previously requiring oral steroids improves QOL and continually 
maintains this improvement.
0113
EFFECTS OF AN INHALED STEROID ON GENERIC QUALITY OF 
LIFE IN ASTHMA O R  COPD
Constant P. van Schayck*, Edw ard Dompeling*, M aureen  P.M .H . 
Rutten***, Hans Folgering**, Guido van den B oom *'***, Chris v a n  
Weel*. ^Department of General Practice, University o f Nijmegen; 
**University Lung Centre Dekkcrswald, University of Nijmegen; 
***Department of Health Economics, University of L im burg , The Neth­
erlands.
In a four-year prospective controlled study we examined the influence o f  
beclomethasone dipropionate (BDP) 400 jig, two times daily, on quality o f  
life in 56 patients with asthma or COPD- During the first two years, patients 
only received bronchodilator therapy with salbutamol or ipratropium bro­
mide. During the third and fourth years, additional treatment with BDP was 
given. 56 Patients (28 asthma, 28 COPD) with an annual decline in the 
forced expiratory volume in one second (FEVj) of at least 80 m l/yr in com­
bination with at least two exacerbations per year during bronchodilator 
therapy alone participated, Quality of life was assessed at the start and after 
two and four years by means of the Inventory of Subjective Health (ISH) and 
the Nottingham Health Profile (NHP). BDP significantly improved the 
course of lung function (FEVj) (p<G.0GQl). However, it did not improve 
the ISH score or the six dimensions of the NHP, neither in asthma, nor i n 
COPD. BDP temporarily decreased respiratory symptoms during months 4-6 
of BDP treatment in asthma (p<0.01) and during months 7-12 in COPD 
(p<0.Q5), A weak correlation was found both cross-sectionally and long i­
tudinally between (change in) symptoms and quality of life on the one and  
the (change in) FEVj on the other hand. It was concluded that although 
BDP significantly improved the course of lung function and temporarily 
decreased the severity of symptoms, it did not improve general well-being of 
patients with asthma or COPD.
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